Search for other papers by Aasem Saif in
Google Scholar
PubMed
Search for other papers by Shrook Mousa in
Google Scholar
PubMed
Search for other papers by Maha Assem in
Google Scholar
PubMed
Search for other papers by Nashwa Tharwat in
Google Scholar
PubMed
Vascular Laboratory, Cairo University, Cairo, Egypt
Search for other papers by Alaa Abdelhamid in
Google Scholar
PubMed
hospital. They were classified into three groups: Group I: Forty patients with overt hypothyroidism (high serum thyroid-stimulating hormone (TSH) and reduced FT4). Group II: Thirty patients with subclinical hypothyroidism (high serum TSH with normal FT4
Search for other papers by Sahar Hossam El Hini in
Google Scholar
PubMed
Search for other papers by Yehia Zakaria Mahmoud in
Google Scholar
PubMed
Search for other papers by Ahmed Abdelfadel Saedii in
Google Scholar
PubMed
Search for other papers by Sayed Shehata Mahmoud in
Google Scholar
PubMed
Search for other papers by Mohamed Ahmed Amin in
Google Scholar
PubMed
Search for other papers by Shereen Riad Mahmoud in
Google Scholar
PubMed
Search for other papers by Ragaa Abdelshaheed Matta in
Google Scholar
PubMed
Introduction Overt hypothyroidism (OH) and subclinical hypothyroidism (SCH) are characterized by the coexistence of traditional cardiovascular disease risk factors, insulin resistance (IR), elevated inflammatory markers, altered hemodynamic
Search for other papers by Akinori Sairaku in
Google Scholar
PubMed
Search for other papers by Yukiko Nakano in
Google Scholar
PubMed
Search for other papers by Yuko Uchimura in
Google Scholar
PubMed
Search for other papers by Takehito Tokuyama in
Google Scholar
PubMed
Search for other papers by Hiroshi Kawazoe in
Google Scholar
PubMed
Search for other papers by Yoshikazu Watanabe in
Google Scholar
PubMed
Search for other papers by Hiroya Matsumura in
Google Scholar
PubMed
Search for other papers by Yasuki Kihara in
Google Scholar
PubMed
Introduction Overt hypothyroidism is known to increase the cardiovascular disorders, and thus there is a consensus to treat it ( 1 , 2 , 3 ), as with hyperparathyroidism ( 4 ). However, it remains controversial whether that is also true for
Search for other papers by Bogumila Urgatz in
Google Scholar
PubMed
Search for other papers by Kris G Poppe in
Google Scholar
PubMed
limit of its pregnancy-specific reference range, when free T4 is within its reference range. Epidemiology of hypothyroidism during pregnancy The prevalence of overt hypothyroidism during pregnancy has been described as about 1–3%, with a higher
Department of Endocrinology and Metabolism, People's Hospital of Liaoning Province, Shenyang, People’s Republic of China
Search for other papers by Ling Shan in
Google Scholar
PubMed
Search for other papers by Yingying Zhou in
Google Scholar
PubMed
Search for other papers by Shiqiao Peng in
Google Scholar
PubMed
Department of Laboratory Medical, The First Hospital of China Medical University, Shenyang, People’s Republic of China
Search for other papers by Xinyi Wang in
Google Scholar
PubMed
Search for other papers by Zhongyan Shan in
Google Scholar
PubMed
Search for other papers by Weiping Teng in
Google Scholar
PubMed
). A previous large cohort study in America used trimester-specific references to classify the definition of hypothyroidism in pregnancy and found that 15.5% of pregnant women had increased TSH during pregnancy, of which 2.4% were overt hypothyroidism
Search for other papers by Xiaoya Zheng in
Google Scholar
PubMed
Search for other papers by Heng Xiao in
Google Scholar
PubMed
Search for other papers by Jian Long in
Google Scholar
PubMed
Search for other papers by Qiang Wei in
Google Scholar
PubMed
Search for other papers by Liping Liu in
Google Scholar
PubMed
Search for other papers by Liping Zan in
Google Scholar
PubMed
Search for other papers by Wei Ren in
Google Scholar
PubMed
presence of hypothyroidism was defined as a TSH value >5.91 µIU/mL with (overt hypothyroidism) or without (subclinical hypothyroidism) decreased FT3 or FT4 levels. Statistical analysis Statistical analyses were performed using GraphPad Prism 5
Search for other papers by Madalena von Hafe in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João, Porto, Portugal
Search for other papers by João Sergio Neves in
Google Scholar
PubMed
Search for other papers by Catarina Vale in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João, Porto, Portugal
Search for other papers by Marta Borges-Canha in
Google Scholar
PubMed
Search for other papers by Adelino Leite-Moreira in
Google Scholar
PubMed
hyperthyroidism ( 50 ). Table 2 Effects of thyroid dysfunction in the cardiovascular system. Hypothyroidism: overt or subclinical Hyperthyroidism: overt or subclinical ↓ heart rate ↑ heart rate ↓ inotropism ↑ myocardial
Search for other papers by Fan Zhang in
Google Scholar
PubMed
Search for other papers by Jian Chen in
Google Scholar
PubMed
Search for other papers by Xinyue Lin in
Google Scholar
PubMed
Search for other papers by Shiqiao Peng in
Google Scholar
PubMed
Search for other papers by Xiaohui Yu in
Google Scholar
PubMed
Search for other papers by Zhongyan Shan in
Google Scholar
PubMed
Search for other papers by Weiping Teng in
Google Scholar
PubMed
= 15), overt hypothyroidism group (OH, n = 15) and SCH group ( n = 15). Rats in the OH and SCH groups were treated by intraperitoneal (i.p.) injection of 3% pentobarbital sodium (0.1 mL/100 g) and underwent thyroidectomy. CON rats underwent sham
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
Search for other papers by Amir Bashkin in
Google Scholar
PubMed
Search for other papers by Eliran Yaakobi in
Google Scholar
PubMed
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
Search for other papers by Marina Nodelman in
Google Scholar
PubMed
Department of Otolaryngology Head and Neck Surgery, Galilee Medical Center, Nahariya, Israel
Search for other papers by Ohad Ronen in
Google Scholar
PubMed
diagnoses: overt hypothyroidism, subclinical hypothyroidism, overt thyrotoxicosis, subclinical thyrotoxicosis and non-thyroidal illness syndrome (NTIS) and/or effect of drugs. It is impossible to differentiate between the latter two based on thyroid function
Search for other papers by L E Zijlstra in
Google Scholar
PubMed
Search for other papers by D M van Velzen in
Google Scholar
PubMed
Search for other papers by S Simsek in
Google Scholar
PubMed
Search for other papers by S P Mooijaart in
Google Scholar
PubMed
Department of Internal Medicine, HagaHospital, The Hague, The Netherlands
Search for other papers by M van Buren in
Google Scholar
PubMed
Search for other papers by D J Stott in
Google Scholar
PubMed
Search for other papers by I Ford in
Google Scholar
PubMed
Search for other papers by J W Jukema in
Google Scholar
PubMed
Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by S Trompet in
Google Scholar
PubMed
overt hyperthyroidism or hypothyroidism were excluded from the initial PROSPER trial. In the current study, participants were excluded when biochemical data regarding TSH was missing. In addition, participants using antithyroid medication, thyroxine